https://www.thebodypro.com/category/atripla-pro/tag/conference-coverage

The Latest

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows Img

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows

Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.

Fewer Renal or Bone Events With Atripla Than Stribild in Large Database Img

Fewer Renal or Bone Events With Atripla Than Stribild in Large Database

Renal adverse events and fractures proved rare among people taking tenofovir disoproxil fumarate (TDF) as part of a single-tablet regimen in a large U.S. database of insured patients.

Complera Non-Inferior to Atripla and Better Tolerated, Study Finds Img

Complera Non-Inferior to Atripla and Better Tolerated, Study Finds

The STaR study compared Complera to Atripla and found that Complera was not only non-inferior to Atripla, it performed better in terms of HIV symptoms and quality of life.

Racial Differences Seen in Comparison of Stribild and Atripla as First-Line Therapy Img

Racial Differences Seen in Comparison of Stribild and Atripla as First-Line Therapy

A new study finds that black people are less likely to keep their viral load down on Atripla -- and that more trouble with side effects may be the reason.

Promo Image

Gilead's Quad Single Tablet Regimen for HIV Non-Inferior to Atripla in Pivotal Phase 3 Study

Seattle, Wash. -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced full Phase 3 clinical trial results from pivotal Study 102 demonstrating that the Quad, a once-daily single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir...

Promo Image

The Once and Future King: What Will Replace Atripla Atop the First-Line HIV Treatment Realm?

Gerald Pierone Jr., M.D.

Atripla (which is a combination of efavirenz + tenofovir + emtricitabine) is the acknowledged king in the realm of first-line antiretroviral therapy.  Le Roi est mort, vive le Roi!  Not so fast: The king still breathes. But ...